Home/ Stocks/ ARVN

Arvinas, Inc

ARVN XNAS

$8.75 +0.07 (+0.81%) ▲ 15-min delayed

Open

$8.81

High

$8.98

Low

$8.64

Volume

1.22M

Market Cap

$567.55M

About Arvinas, Inc

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 246 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$249.70M	$169.40M	$2.61
Q1 2026	$15.60M	$-57,600,000	$-0.90
Q3 2025	$41.90M	$-35,100,000	$-0.48
Q2 2025	$22.40M	$-61,200,000	$-0.84

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for ARVN yet. Check out our latest market news or earnings calendar.

Get ARVN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Arvinas, Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.